Lupin receives 6 observations from USFDA for Nagpur Injectable facility

The U.S. FDA has conducted an inspection of Lupin's Nagpur Injectable facility from September 8 to September 16, 2025. The inspection closed with six observations.

We will address the observations and respond to the U.S. FDA within the stipulated timeframe. We are committed to be compliant with CGMP quality standards across all our facilities.

Shares of Lupin Limited was last trading in BSE at Rs. 2051.30 as compared to the previous close of Rs. 2046.85. The total number of shares traded during the day was 14587 in over 1892 trades.

The stock hit an intraday high of Rs. 2063.60 and intraday low of 2018.25. The net turnover during the day was Rs. 29907723.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA Inspection Nagpur InjectableFacility 6Observations